Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China

Table 2 Baseline characteristics of hepatitis C virus patients based on genotype

	Total (n = 366)	Genotype 1 (n = 216)	Genotype 2 (n = 126)	Genotype 3 (n = 24)
Age (yr)	52.2 ± 12.0	51.7 ± 12.8	53.6 ± 10.0	49.8 ± 14.1
Gender (males, %)	174 (47.5)	101 (46.8)	62 (49.2)	11 (45.8)
TBIL (µmol/L)	19.63 ± 10.60	19.62 ± 10.77	19.52 ± 10.72	20.07 ± 8.47
ALT (U/L)	53.48 ± 45.18	56.95 ± 47.79	51.55 ± 40.35	54.33 ± 36.91
AST (U/L)	51.89 ± 39.12	50.79 ± 41.96	48.9 ± 33.74	53.5 ± 33.31
Albumin (g/L)	36.6 ± 8.6	38.9 ± 8.6	41.2 ± 8.5	36.6 ± 8.6
TCHO (mmol/L)	3.85 ± 0.60	3.81 ± 0.58	3.85 ± 0.66	4.14 ± 0.41
Hemoglobin (mg/dL)	120.3 ± 23.6	120.4 ± 23.3	121.2 ± 23.2	114.8 ± 27.9
Platelets (109/L)	147.7 ± 75.8	144.5 ± 74.8	155.7 ± 77.8	134.3 ± 73.6
AFP (ng/mL)	4.69 ± 5.79	5.01 ± 7.33	4.30 ± 2.02	3.81 ± 2.27
Treatment experienced, n (%)	50 (13.7)	26 (12.0)	20 (15.9)	4 (16.7)
Cirrhosis, n (%)	154 (42.1)	96 (43.5)	46 (36.5)	12 (50)
HBV/HCV co-infection, n (%)	25 (6.8)	12 (5.6)	9 (7.1)	4 (16.7)
Diabetes mellitus, n (%)	17 (4.6)	12 (5.6)	4 (3.2)	1 (4.2)
Hypertension, n (%)	24 (6.6)	16 (7.4)	8 (6.3)	0 (0)
Fatty liver disease, n (%)	52 (14.2)	31 (14.4)	16 (12.7)	5 (20.8)

TBil: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TCHO: Total cholesterol; AFP: Alpha fetoprotein; HCV: Hepatitis C virus; HBV: Hepatitis B virus.